Literature DB >> 28102301

Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.

Shu Su, Bian Hu, Jie Shao, Bin Shen, Juan Du, Yinan Du, Jiankui Zhou, Lixia Yu, Lianru Zhang, Fangjun Chen, Huizi Sha, Lei Cheng, Fanyan Meng, Zhengyun Zou, Xingxu Huang, Baorui Liu.   

Abstract

Entities:  

Year:  2017        PMID： 28102301      PMCID： PMC5244626          DOI： 10.1038/srep40272

Source DB:  PubMed          Journal:  Sci Rep        ISSN： 2045-2322            Impact factor:   4.379


× No keyword cloud information.
In figure 4d the micrograph for Patient 1 at 7 days was inadvertently duplicated for the Healthy Donor at day 7. The correct figure 4d appears below as Figure 1.
Figure 1
  3 in total

1.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

Review 2.  Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy.

Authors:  Lin Shui; Xi Yang; Jian Li; Cheng Yi; Qin Sun; Hong Zhu
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 7.561

Review 3.  Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.

Authors:  Xinjie Xu; Qihang Sun; Xiaoqian Liang; Zitong Chen; Xiaoli Zhang; Xuan Zhou; Meifang Li; Huilin Tu; Yu Liu; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2019-11-12       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.